IL227295A0 - diagnostic method - Google Patents

diagnostic method

Info

Publication number
IL227295A0
IL227295A0 IL227295A IL22729513A IL227295A0 IL 227295 A0 IL227295 A0 IL 227295A0 IL 227295 A IL227295 A IL 227295A IL 22729513 A IL22729513 A IL 22729513A IL 227295 A0 IL227295 A0 IL 227295A0
Authority
IL
Israel
Prior art keywords
diagnostic method
diagnostic
Prior art date
Application number
IL227295A
Other languages
English (en)
Hebrew (he)
Original Assignee
Cytosystems Ltd Gb
David Galloway
Nick Coleman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytosystems Ltd Gb, David Galloway, Nick Coleman filed Critical Cytosystems Ltd Gb
Publication of IL227295A0 publication Critical patent/IL227295A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL227295A 2011-01-07 2013-07-02 diagnostic method IL227295A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1100223.5A GB201100223D0 (en) 2011-01-07 2011-01-07 Diagnostic method
PCT/GB2012/000008 WO2012093251A1 (en) 2011-01-07 2012-01-06 Diagnostic method

Publications (1)

Publication Number Publication Date
IL227295A0 true IL227295A0 (en) 2013-09-30

Family

ID=43663908

Family Applications (1)

Application Number Title Priority Date Filing Date
IL227295A IL227295A0 (en) 2011-01-07 2013-07-02 diagnostic method

Country Status (8)

Country Link
US (1) US10107814B2 (enExample)
EP (2) EP3214445B1 (enExample)
JP (1) JP2014501929A (enExample)
AU (1) AU2012204796A1 (enExample)
CA (1) CA2823460A1 (enExample)
GB (1) GB201100223D0 (enExample)
IL (1) IL227295A0 (enExample)
WO (1) WO2012093251A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11054426B2 (en) * 2011-01-07 2021-07-06 Cytosystems Ltd Diagnostic method
US11519916B2 (en) 2015-06-08 2022-12-06 Arquer Diagnostics Limited Methods for analysing a urine sample
ES2911415T3 (es) 2015-06-08 2022-05-19 Arquer Diagnostics Ltd Métodos y kits
GB201511196D0 (en) 2015-06-25 2015-08-12 Cytosystems Ltd Monoclonal antibodies
WO2021242637A1 (en) * 2020-05-28 2021-12-02 Cytobay Inc. Cytopathological staining
EP4217746A1 (en) * 2020-09-24 2023-08-02 Cytosystems Limited Diagnosis of cancer by imaging flow cytometry

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303323B1 (en) * 1997-10-21 2001-10-16 Cancer Research Campaign Technology Limited Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies
EP1888238B1 (en) * 2005-04-21 2014-08-13 California Institute of Technology Parylene membrane filters

Also Published As

Publication number Publication date
GB201100223D0 (en) 2011-02-23
JP2014501929A (ja) 2014-01-23
US10107814B2 (en) 2018-10-23
AU2012204796A1 (en) 2013-08-01
EP3214445A1 (en) 2017-09-06
EP3214445B1 (en) 2018-11-14
US20130059930A1 (en) 2013-03-07
WO2012093251A1 (en) 2012-07-12
CA2823460A1 (en) 2012-07-12
EP2661628A1 (en) 2013-11-13
EP2661628B1 (en) 2016-12-21

Similar Documents

Publication Publication Date Title
GB2500163B (en) Method
GB2493207B (en) Method
HUP1200607A2 (en) Diagnostic method
ZA201402224B (en) Diagnostic apparatus
GB201116530D0 (en) Method
GB201008719D0 (en) Diagnostic method
AP2013007084A0 (en) Diagnostic method
GB201016161D0 (en) Diagnostic method
IL227295A0 (en) diagnostic method
GB201218341D0 (en) Diagnostic method
GB201105436D0 (en) Method
ZA201301498B (en) Diagnostic method
GB201212757D0 (en) Method
GB201121301D0 (en) Method
GB201114919D0 (en) Method
GB201114325D0 (en) Method
GB201101219D0 (en) Method
GB201117230D0 (en) Connection method
GB201117476D0 (en) Method
GB201117358D0 (en) Method
GB201111673D0 (en) Method
GB201111189D0 (en) Method
EP2661625A4 (en) DIAGNOSTIC PROCEDURE
GB201115783D0 (en) Method
GB201108041D0 (en) Method